Patients with the most severe form of generalised epilepsy saw a 77% drop in their most dangerous seizures after receiving NeuroPace’s brain implant, according to 18-month trial data the company detailed on its Q1 2026 earnings call last week. Those seizures, called generalised tonic-clonic episodes, are the violent convulsive events that carry the highest risk of injury, hospitalisation, and sudden unexpected death in epilepsy patients. The same earnings call delivered first-quarter revenue of $22.1 million (up roughly 20% year-on-year), full-year 2026 guidance raised to $99-101 million, and an FDA clock pause on the expanded-indication review the trial is designed to support.
The Q1 numbers
NeuroPace booked $22.1 million in total Q1 2026 revenue. The core RNS System (its implantable closed-loop brain stimulator that detects abnormal brain activity and responds with corrective electrical pulses) accounted for $21.7 million of that, up 19.5% from $18.2 million in Q1 2025. Non-GAAP revenue excluding the company’s recently acquired DIXI Medical EEG-recording business rose 20.1%. NeuroPace raised full-year 2026 revenue guidance to $99-101 million from a previous range of $98-100 million, implying 21-23% growth for the core RNS business. CEO Joel Becker noted on the call that the new guidance does not yet include any revenue from a potential expanded indication; if FDA approval lands by midyear as anticipated, that contribution would begin in the second half.
What NAUTILUS is testing
The RNS System is currently FDA-approved for adults with focal drug-resistant epilepsy, the form where seizures originate from a specific brain region and have not responded to medication. NAUTILUS is the pivotal trial designed to expand that approval into idiopathic generalised epilepsy, a different form where seizures emerge from multiple brain regions simultaneously. The patient population is several times larger than the current focal-epilepsy label.
The 18-month follow-up data, first presented at the American Academy of Neurology annual meeting in April 2026 and revisited on the 12 May earnings call, showed three concrete clinical outcomes in a highly refractory patient population: a 77% median reduction in generalised tonic-clonic seizures, more than a 30% reduction in injury events, and a 44% reduction in benzodiazepine rescue medication usage. Those numbers map directly onto patient mortality and emergency healthcare usage. Generalised tonic-clonic seizures are the seizure type most likely to send a patient to the hospital and the seizure type most associated with sudden unexpected death in epilepsy.
FDA clock pause
The FDA exercised a 180-day clock pause on NeuroPace’s NAUTILUS PMA supplement during the agency’s mid-cycle review, requesting additional information and clarification. NeuroPace responded and characterised the pause on the earnings call as a standard request rather than a substantive concern. Becker noted that the device’s existing Breakthrough Device Designation continues to enable more consistent interaction and timely feedback during the review. The company still expects a midyear 2026 FDA determination. A positive determination would add idiopathic generalised epilepsy to the RNS System’s labelled indications and substantially expand the addressable patient pool.
Inside the WISeR cycle
The Q1 print lands inside a regulatory window NeuroPace is winning. Inside BCI covered on 8 May the CMS WISeR rule that moved Inspire Medical’s hypoglossal nerve stimulator onto prior authorization while leaving the RNS System off the WISeR services list entirely. The 12 May numbers are the first hard quarterly print confirming the upside half of that bifurcation. NeuroPace posted +20% revenue growth and raised guidance in the same window that Inspire cut its full-year outlook on the same regulatory cycle.
What to watch
The next NeuroPace-specific signal is the FDA determination on the NAUTILUS PMA supplement, expected midyear. Beyond NeuroPace, the broader bioelectronic-medicine commercial inflection Inside BCI tracked on 5 May continues to harden. Friday’s CVRx Humana coverage win extends the same payer-side scaffolding pattern from epilepsy to heart failure. Closed-loop and adaptive implantable devices are pulling away from open-loop incumbents in revenue growth, payer coverage, and regulatory cycle outcomes alike.
Sources
- NeuroPace (NPCE) Q1 2026 Earnings Transcript (Motley Fool, 14 May 2026)
- NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance (Yahoo Finance / company release)
- NeuroPace signals $99M-$101M 2026 revenue outlook while targeting 21%-23% underlying RNS growth (Seeking Alpha)
- NeuroPace revenue up 20.1% to USD 22.1M in Q1 2026 (Medical Buyer)
- NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS System Indication for Idiopathic Generalized Epilepsy (BusinessWire, 17 Dec 2025)